Q3
CNXU — Q3 FY2026 Financial Report Analysis
Conexeu Sciences, a pre-revenue regenerative medicine company that direct-listed on Nasdaq in May 2026, posted a $7.7M quarterly net loss — roughly $6.5M of it consulting, business development and management pay — while pushing its FDA 510(k) submission to March 2027 and ending the quarter with under $2M of cash and a going-concern warning.